Orum Therapeutics

We’re looking forward to sharing new data tomorrow on our PROTAb platform at the ADC Linker and Conjugation Summit in Boston. Our Principal Scientist, Qinsi Zheng, will be presenting a poster, entitled, “PROTAb Platform: An Innovative Universal Linker for DACs with Cereblon-Based Degraders.” See the image below or the agenda here for more info: https://lnkd.in/eQWiftp7 #degraderantibodyconjugates #ADC #ADCs #antibodydrugconjugates #targetedproteindegradation

We are excited to share our participation at the ADC & Radiopharmaceuticals Pharma & Biotech Partnering Summit September 9-10, in Boston. Greg Dwyer will be sharing his thoughts and experience at multiple sessions during the summit, and Orum looks forward to connecting with potential partners to advance our platforms and products together. #ADC #DAC https://ter.li/faxa7i

We’re excited to announce a global, multi-target license and option agreement with Vertex Pharmaceuticals for the use of Orum’s Dual-Precision Targeted Protein Degradation (TPD²®) technology to develop novel degrader-antibody conjugates as targeted conditioning agents for use with gene editing. Read the release here: https://lnkd.in/gyguMg8v #TPD #targetedproteindegradation #ADC #ADCs #antibodydrugconjugates

Greg Dwyer will be introducing our novel payload ADCs at 'ADC Payload Summit 2024 - Expanding the Toolbox of ADC Payloads to Improve Efficacy, Diversify Mode of Action & Overcome Resistance Challenges'. #ADC #DAC #oncology

We're excited for the 14th Annual World ADC London 2024 next week! Orum's Head of Business Development Greg Dwyer will be in London as a panel discussant highlighting the value of collaborations for mutual success.

We're hiring for a Director / Sr. Director of CMC - come help lead our innovative and exciting science into the clinic! https://lnkd.in/eSxjKmf9

We are growing again and looking for great candidates with ADC chemistry leadership who are excited to develop next-gen therapies! Know anyone who might be interested? #hiring

Thanks BioSpace for talking to our CEO Sung Joo Lee about how Orum is taking a different approach to antibody drug conjugates with our TPS²™ (targeted protein degradation) approach, diversifying payloads and opening the therapeutic window. Read the article here: https://lnkd.in/gRbjnT9A #TPD #targetedproteindegradation #antibodydrugconjugates #ADCs #oncology #cancer

We’re excited to announce that Bristol Myers Squibb has acquired Orum’s ORM-6151 program, a first-in-class, anti-CD33 antibody-enabled GSPT1 degrader for acute myeloid #leukemia or myelodysplastic syndrome. ORM-6151 is the second program from our Dual-Precision Targeted Protein Degradation (TPD² ™) approach to build novel targeted protein degraders combined with the precise tumor cell delivery mechanisms of antibodies to generate innovative, first-in-class, cell-specific TPDs for the treatment of #cancer. Read the release here: https://lnkd.in/gXvbVP53 #TPD #targetedproteindegradation #ADC #ADCs #antibodydrugconjugates #oncology #AML